Tumor cell metabolism: cancer's Achilles' heel.
暂无分享,去创建一个
[1] G. Semenza,et al. Hypoxia-Inducible Factor 1 (HIF-1) Pathway , 2007, Science's STKE.
[2] G. Kayser,et al. Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. , 2007, Oncology reports.
[3] L. Cantley,et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.
[4] Z. Bhujwalla,et al. Choline kinase alpha in cancer prognosis and treatment. , 2007, The Lancet. Oncology.
[5] P. Krammer,et al. Tumor Immunology , 2018, Medical Immunology.
[6] Richard D. Vaughan-Jones,et al. Regulation of tumor pH and the role of carbonic anhydrase 9 , 2007, Cancer and Metastasis Reviews.
[7] A. Morris,et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin , 2006, Diabetologia.
[8] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[9] P. Leder,et al. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.
[10] S. Henderson,et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production , 2007, Proceedings of the National Academy of Sciences.
[11] J. Pouysségur,et al. The Expanding Family of Eucaryotic Na+/H+Exchangers* , 2000, The Journal of Biological Chemistry.
[12] Chi V. Dang,et al. The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.
[13] L. Galluzzi,et al. Mitochondria as therapeutic targets for cancer chemotherapy , 2006, Oncogene.
[14] Adrian L Harris,et al. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. , 2006, Cancer research.
[15] J. Pouysségur,et al. Hypoxia signalling controls metabolic demand. , 2007, Current opinion in cell biology.
[16] Ru Wei,et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.
[17] H. Nawashiro,et al. L‐type amino acid transporter 1 as a potential molecular target in human astrocytic tumors , 2006, International journal of cancer.
[18] D. Spitz,et al. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. , 2007, Cancer research.
[19] S. Edlbacher,et al. Über den Stoffwechsel der Tumoren. IV. Mitteilung. , 2022 .
[20] J. Testa,et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells , 2005, Oncogene.
[21] Oksana Gavrilova,et al. p53 Regulates Mitochondrial Respiration , 2006, Science.
[22] C. Culmsee,et al. p53 in neuronal apoptosis. , 2005, Biochemical and biophysical research communications.
[23] A. Ullrich,et al. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. , 2007, Cancer research.
[24] R. Jaenisch,et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. , 2003, Cell.
[25] C. Boschek,et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. , 2005, Seminars in cancer biology.
[26] Mark Muzi,et al. Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond , 2007, Clinical Cancer Research.
[27] S. Miyamoto,et al. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II , 2008, Cell Death and Differentiation.
[28] A. Lardner. The effects of extracellular pH on immune function , 2001, Journal of leukocyte biology.
[29] Kou-Juey Wu,et al. Direct regulation of TWIST by HIF-1α promotes metastasis , 2008, Nature Cell Biology.
[30] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[31] John Condeelis,et al. Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.
[32] N. Hay,et al. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt , 2006, Oncogene.
[33] Eyal Gottlieb,et al. TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.
[34] Sébastien Bonnet,et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.
[35] G. Semenza,et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. , 2007, Cancer cell.
[36] P. Pedersen,et al. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen , 2007, Journal of bioenergetics and biomembranes.
[37] D. Brizel,et al. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Hayashi,et al. ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis , 2008, Science.
[39] Lorenzo Galluzzi,et al. Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.
[40] N. Denko,et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.
[41] J. Pouysségur,et al. Oxygen, Hypoxia, and Stress , 2007, Annals of the New York Academy of Sciences.
[42] R. Raval,et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. , 2006, Cancer research.
[43] E. Gottlieb,et al. Cell-Permeating α-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells , 2007, Molecular and Cellular Biology.
[44] M. Zoratti,et al. The mitochondrial permeability transition. , 1995, Biochimica et biophysica acta.
[45] R. Shaw,et al. Glucose metabolism and cancer. , 2006, Current opinion in cell biology.
[46] G. Cheon,et al. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma , 2007, Molecular Cancer Therapeutics.
[47] G. Kroemer,et al. Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.
[48] D. Munn,et al. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.
[49] Martin G Pomper,et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. , 2004, Biochemical and biophysical research communications.
[50] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[51] L. Zitvogel,et al. Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.
[52] F. López-Ríos,et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. , 2007, Cancer research.
[53] R. Gillies,et al. Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.
[54] A. Monks,et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. , 2005, Cancer research.
[55] Marty C. Brandon,et al. Mitochondrial mutations in cancer , 2006, Oncogene.
[56] P. Comoglio,et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.
[57] Gregor Rothe,et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.
[58] David Beach,et al. Glycolytic enzymes can modulate cellular life span. , 2005, Cancer research.
[59] J. Griffiths,et al. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. , 2006, Cancer research.
[60] A. Maitra,et al. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck , 2007, Proceedings of the National Academy of Sciences.
[61] Tao Wang,et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. , 2007, The Journal of clinical investigation.
[62] G. Semenza,et al. Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 , 2007, Molecular and Cellular Biology.
[63] Daniel E Bauer,et al. ATP citrate lyase inhibition can suppress tumor cell growth. , 2005, Cancer cell.
[64] G. Semenza,et al. HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells , 2007, Cell.
[65] Jonathan Pevsner,et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. , 2007, Cancer cell.
[66] J. Swinnen,et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. , 2007, Cancer research.
[67] H. Christofk,et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.
[68] U. Grohmann,et al. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation , 2007, Nature Reviews Immunology.
[69] Quynh-Thu Le,et al. Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.
[70] R. Jaenisch,et al. HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation , 2003, Cell.
[71] R. Deberardinis,et al. Phosphatidylinositol 3-Kinase-dependent Modulation of Carnitine Palmitoyltransferase 1A Expression Regulates Lipid Metabolism during Hematopoietic Cell Growth* , 2006, Journal of Biological Chemistry.
[72] S. Pastoreková,et al. Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. , 2007, American journal of physiology. Cell physiology.
[73] Eyal Gottlieb,et al. Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.
[74] H. Yee,et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. , 2007, Molecular cell.
[75] C. Supuran,et al. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. , 2006, Trends in pharmacological sciences.
[76] G. Semenza,et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.
[77] K. Tachibana,et al. Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. , 2006, Journal of the National Cancer Institute.
[78] J. Pouysségur,et al. Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.
[79] Yong-Ho Ahn,et al. Up-regulation of Acetyl-CoA Carboxylase α and Fatty Acid Synthase by Human Epidermal Growth Factor Receptor 2 at the Translational Level in Breast Cancer Cells* , 2007, Journal of Biological Chemistry.
[80] A. Ortega,et al. Glucose avidity of carcinomas. , 2009, Cancer letters.
[81] J. Hoek,et al. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. , 2005, Cancer research.
[82] M. Dewhirst,et al. Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. , 2007, Cancer research.